软组织肉瘤的全身治疗：过去、现在与未来
Systemic therapy in soft tissue sarcomas: past, present and future.
作者信息
Purohit Samit, Bhise Rohan, Appachu Sandhya, Lakshmaiah K C, Govindbabu K
机构信息
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr M.H Marigowda road, Bangalore, -560029 India.
出版信息
Indian J Surg Oncol. 2011 Dec;2(4):327-31. doi: 10.1007/s13193-012-0140-8. Epub 2012 Mar 8.
Soft tissue sarcomas (STS) comprise 1% of all cancers diagnosed worldwide with more than 40 different histological subtypes each with distinct underlying biology, natural history and response to treatment. Due to the differential chemosensitivity it is imperative to have a correct histological diagnosis for optimal treatment of these patients. Even though surgery remains the primary modality of treatment there is increasing specialization of chemotherapy with respect to histological subtype. In general there is no place for "one size fits all strategy". To correctly define the role of chemotherapy, an extensive search was carried out online and offline for all relevant articles concerning chemotherapy in soft tissue sarcoma. This review aims to discuss the evolution of chemotherapy, its present role in neoadjuvant, adjuvant, metastatic settings and exciting trends with the advent of targeted therapies.
软组织肉瘤（STS）占全球所有确诊癌症的1%，有40多种不同的组织学亚型，每种亚型都有独特的潜在生物学特性、自然病史和对治疗的反应。由于化疗敏感性存在差异，对这些患者进行最佳治疗时，正确的组织学诊断至关重要。尽管手术仍然是主要的治疗方式，但针对组织学亚型的化疗专业化程度正在提高。一般来说，“一刀切”的策略并不适用。为了正确界定化疗的作用，我们在网上和线下广泛搜索了所有关于软组织肉瘤化疗的相关文章。本综述旨在讨论化疗的发展历程、其在新辅助、辅助、转移性治疗中的当前作用以及随着靶向治疗出现的令人兴奋的趋势。
Zotero 插件